Article
Cell Biology
Ahmed S. Elkateb, Shahira Nofal, Sahar A. Ali, Hanaa B. Atya
Summary: The study investigated a novel combination of sorafenib and Camptothecin (CPT) to enhance sorafenib's ferroptosis action and reduce sorafenib resistance in hepatocellular carcinoma (HCC) treatment. The combination significantly increased lipid peroxidation and iron concentration, decreased total antioxidant capacity, glutathione peroxidase and glutathione reductase activity, and reduced the expression of Nrf2 and SLC7A11. Inhibition of Nrf2 improved sorafenib's sensitivity and reduced resistance, enhancing its ferroptosis action.
Article
Oncology
Yun Wang, Kai Tan, Wen Hu, Yan Hou, Guang Yang
Summary: This study identifies a novel long non-coding RNA (lncRNA), AC026401.3, that promotes sorafenib and lenvatinib resistance in HCC cells. The findings suggest that targeting the AC026401.3-OCT1-E2F2 signaling axis could be a promising strategy for HCC therapeutics.
EXPERIMENTAL CELL RESEARCH
(2022)
Article
Oncology
Chaoran Shi, Dora Lai-Wan Kwong, Xue Li, Xia Wang, Xiaona Fang, Liangzhan Sun, Ying Tang, Xin-Yuan Guan, Shan-Shan Li
Summary: Hepatocellular cancer (HCC) is a lethal subtype of liver cancer, and effective therapeutics are lacking. Understanding and targeting cancer stem cells (CSCs) can revolutionize cancer management. Maelstrom (MAEL) is implicated in the regulation of CSC phenotypes, and our study demonstrates that MAEL positively regulates cancer stem-cell-like properties in HCC. MAEL silencing enhances tumor cells' sensitivity to sorafenib. Our study also reveals the involvement of the MAEL-dependent PGST2/IL8/AKT/STAT3 signaling pathway in the regulation of stemness. Targeting the MAEL/PGST2 axis may be a potential therapeutic strategy against CSC and sorafenib resistance in HCC.
Article
Biochemistry & Molecular Biology
Jialei Sun, Chenhao Zhou, Yue Zhao, Xiaofei Zhang, Wanyong Chen, Qiang Zhou, Bo Hu, Dongmei Gao, Lisa Raatz, Zhefang Wang, Peter J. Nelson, Yuchao Jiang, Ning Ren, Christiane J. Bruns, Haijun Zhou
Summary: QSOX1 acts as a cellular prooxidant in HCC, sensitizing cells to oxidative stress by inhibiting NRF2. There is a negative correlation between QSOX1 and NRF2 expression in tumor tissues from HCC patients, and QSOX1 can enhance sorafenib-induced ferroptosis.
Article
Biochemistry & Molecular Biology
Huan Zhao, Xi Cheng, Judian Yu, Yong Li
Summary: HCC cells that are resistant to sorafenib show characteristics of epithelial-mesenchymal transition (EMT) with increased expression of the core factor Snail. Upregulation of protein stability, particularly through ATM and CSN2, is responsible for the increased expression of Snail in these resistant cells. Targeted inhibition of Snail may help overcome sorafenib resistance in HCC patients.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
(2021)
Article
Biochemistry & Molecular Biology
Junjie Xu, Lin Ji, Yeling Ruan, Zhe Wan, Zhongjie Lin, Shunjie Xia, Liye Tao, Junhao Zheng, Liuxin Cai, Yifan Wang, Xiao Liang, Xiujun Cai
Summary: The study investigated the role of ROS in sorafenib resistance, showing suppressed ROS levels in sorafenib-resistant HCC cells, along with reduced mitochondria numbers likely caused by accelerated degradation of PGC1 beta. Mechanistic dissection revealed that UBQLN1 induced PGC1 beta degradation to attenuate mitochondrial biogenesis and ROS production in sorafenib-resistant cells. Clinical investigations further indicated that higher UBQLN1 levels led to worse recurrence-free survival in patients.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2021)
Article
Biochemistry & Molecular Biology
Ruiqi Zheng, Shuang Weng, Jianping Xu, Zhuo Li, Yaru Wang, Zulihumaer Aizimuaji, Sheng Ma, Linlin Zheng, Haiyang Li, Wantao Ying, Weiqi Rong, Ting Xiao
Summary: This study explores the potential mechanisms by which pretreatment factors affect sorafenib resistance using proteomic techniques. The activation level of the redundant PI3K/AKT pathway, biotransformation capacity, and autophagy level in hepatocellular carcinoma patients prior to sorafenib treatment might affect their sensitivity to sorafenib, with ADH1A and STING1 being key molecules. These three factors could interact mechanistically to promote tumor cell survival, representing malignant features of tumor cells and having implications for hepatocellular carcinoma prognosis. Our study suggests potential therapeutic interventions for patients with sorafenib resistance and highlights the potential application of immunotherapy to improve their survival.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL
(2023)
Article
Oncology
Bisha Ding, Chang Bao, Luqi Jin, Liang Xu, Weimin Fan, Weiyang Lou
Summary: The study demonstrated that CASK expression was positively associated with sorafenib resistance and poor prognosis in hepatocellular carcinoma (HCC) patients. Inhibition of CASK increased the sensitivity to sorafenib by promoting apoptosis and autophagy, while CASK overexpression led to the opposite effects. CASK may serve as a promising biomarker and potential therapeutic target for HCC.
FRONTIERS IN ONCOLOGY
(2021)
Article
Pharmacology & Pharmacy
Xiang-Peng Tan, Ben-Han Xiong, Yuan-Xu Zhang, Shen-Li Wang, Qian Zuo, Jing Li
Summary: This study discovered the highly expressed FXYD5 in sorafenib-resistant HCC cells and its higher expression level in HCC tissues compared to par-acancerous tissues. The downregulation of FXYD5 reversed the resistance of Huh7/sora cells to sorafenib, while overexpression of FXYD5 reduced the sensitivity of HCC cells to sorafenib. Additionally, abnormal activation of the Akt/mTOR signaling pathway was found in Huh7/sora cells, and MK2206, an Akt inhibitor, increased the sensitivity of HCC cells to sorafenib. The expression level of p-Akt was positively correlated with the expression of FXYD5 in HCC tissues.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Ziyue Wang, Cuicui Wu, Jinren Liu, Shunxin Hu, Junli Yu, Qiangqiamg Yin, Hongda Tian, Zhipeng Ding, Guiqiang Qi, Li Wang, Liguo Hao
Summary: In this study, a novel nanodrug carrier system was developed for accurate and efficient delivery of Sorafenib (SRF), improving its therapeutic effects and achieving tumor-specific imaging. The system was able to specifically bind to glypican-3 (GPC3) receptors on hepatocellular carcinoma (HCC) cells and release the loaded SRF under tumor microenvironment (TME) conditions. The in vitro and in vivo experiments demonstrated the effectiveness of the system in inhibiting HCC cell proliferation and tumor growth.
Article
Pharmacology & Pharmacy
Xin Guan, Yi Wu, Shuqin Zhang, Zhiyi Liu, Qingjie Fan, Shuai Fang, Sennan Qiao, Fei Sun, Chongyang Liang
Summary: This study evaluated patient samples' response to sorafenib using PDX models and single-cell sequencing technology, identifying a specific cell cluster highly activated by JUN transcription factors that may lead to a poor response to sorafenib. These findings may provide a novel approach for the treatment of sorafenib-resistant HCC.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Gregory Fouquet, Constance Marie, Louison Collet, Catherine Vilpoux, Hakim Ouled-Haddou, Eric Nguyen-Khac, Jagadeesh Bayry, Mickael Naassila, Ingrid Marcq, Hicham Bouhlal
Summary: This study demonstrates the issue of acquired resistance in sorafenib treatment for advanced hepatocellular carcinoma. It shows that sorafenib-resistant cells lose expression of the tumor suppressor receptor SLAMF3, leading to increased aggressiveness and epithelial-to-mesenchymal transition. Interestingly, the overexpression of SLAMF3 can reverse the epithelial-to-mesenchymal transition and decrease metastatic potential, making it a potential therapeutic and diagnostic tool for managing sorafenib treatment.
Article
Oncology
Kezhong Tang, Qing Chen, Yanmo Liu, Lantian Wang, Wenjie Lu
Summary: This study found that the combination treatment of metformin and sorafenib can inhibit the proliferation of HCC cells by inducing ferroptosis. Additionally, the study revealed the role of the p62-Keap1-Nrf2/HO1 signaling pathway in the combination treatment.
Review
Biochemistry & Molecular Biology
Chun- Wang, Pei-Ming Chu, Yi-Li Chen, Yang-Hsiang Lin, Cheng-Yi Chen
Summary: Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality worldwide, often associated with inflammation and drug resistance post-chemotherapy. Understanding the role of cytokines in HCC pathogenesis can help overcome inflammatory reactions and cytokine secretion, ultimately counteracting chemotherapeutic resistance.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Haisu Tao, Yuxin Zhang, Jiang Li, Junjie Liu, Tong Yuan, Wenqiang Wang, Huifang Liang, Erlei Zhang, Zhiyong Huang
Summary: This study found that the lncRNA BBOX1-AS1 promotes tumor progression and drug resistance in HCC by upregulating PHF8. BBOX1-AS1 enhances the stability of PHF8 mRNA by targeting miR-361-3p, leading to tumor progression and autophagy. These findings suggest that BBOX1-AS1 promotes HCC progression and sorafenib resistance through the miR-361-3p/PHF8 axis.
MOLECULAR THERAPY-ONCOLYTICS
(2023)
Review
Oncology
Suna Zhou, Xuefeng Sun, Zhicheng Jin, Haihua Yang, Wenguang Ye
Summary: This article summarizes the regulatory role of autophagy in esophageal cancer and highlights its significance in the initiation, progression, tumor microenvironment modification, diagnosis, and treatment of esophageal cancer.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2022)
Article
Immunology
Songzhe Piao, Lan Zheng, Haihong Zheng, Mengya Zhou, Qin Feng, Suna Zhou, Mang Ke, Haihua Yang, Xuequan Wang
Summary: This study found that the PDLIM gene family is closely associated with the occurrence and progression of prostate cancer. Among them, PDLIM2 is associated with epithelial-mesenchymal transition and immune cell infiltration in prostate cancer, and may serve as a potential prognostic biomarker.
JOURNAL OF IMMUNOLOGY RESEARCH
(2022)
Review
Oncology
Suna Zhou, Yinnan Meng, Xuefeng Sun, Zhicheng Jin, Wei Feng, Haihua Yang
Summary: Adaptive radiotherapy (ART) is a new radiotherapy technology that uses image guidance to avoid overexposure of residual tumors and normal tissues. This article explores who can benefit from ART, when is the optimal time to conduct ART, and how to implement ART effectively.
Article
Biotechnology & Applied Microbiology
Qian Li, Dongdong Tong, Xintao Jing, Peihan Ma, Fang Li, Qiuyu Jiang, Jinyuan Zhang, Hua Wen, Manli Cui, Chen Huang, Mingxin Zhang
Summary: The expression of TEAD4-MAD2L1 axis is associated with proliferation and metastasis of colorectal cancer (CRC) cells. Inhibiting the expression of MAD2L1 or TEAD4 can suppress proliferation and migration of CRC cells and promote apoptosis. MAD2L1 and TEAD4 are potential biomarkers for colorectal cancer.
CANCER GENE THERAPY
(2023)
Article
Chemistry, Multidisciplinary
Yujie Zhang, Jingjie Zhao, Lingmin Zhang, Yuanru Zhao, Yuanyuan Zhang, Liangliang Cheng, Dan Wang, Cui Liu, Mingxin Zhang, Kelong Fan, Mingzhen Zhang
Summary: Ultrasound-triggered sonodynamic therapy (SDT) has emerged as a promising approach for eradicating deep-seated solid tumors. In this study, a cascade nanoreactor (CCP@HP@M) was designed to enhance the antitumor efficiency of SDT on colorectal cancer by incorporating sonosensitizer Ce6 and autophagy inhibitor chloroquine. CCP@HP@M effectively accumulated in tumor cells, resulting in enhanced SDT efficiency for eliminating tumor cells in vitro and in vivo. This cascade nanoreactor could stimulate apoptosis and ferroptosis by alleviating hypoxia, enhancing ROS generation, and inhibiting protective autophagy pathway.
Article
Oncology
Chao Zhou, Liqiao Hou, Xingni Tang, Changxing Liu, Yinnan Meng, Haijian Jia, Haihua Yang, Suna Zhou
Summary: This study investigated the application of a CT stimulation-based radiomics model for screening patients with locally advanced non-small cell lung cancer (NSCLC) who can benefit from adaptive radiotherapy (ART). The results showed that the model could effectively predict the efficacy of ART, and ART had significant benefits in the lung, heart, cord, and esophagus. This study provides guidance and promotes the application of ART in the clinic.
RADIOTHERAPY AND ONCOLOGY
(2023)
Review
Medicine, General & Internal
Ling Fan, Ning Lu, Lingmin Zhang, Jie Zhang, Jie Li, Manli Cui, Mingxin Zhang
Summary: In this systematic meta-analysis, the authors found that programmed death 1 (PD-1) inhibitors plus chemotherapy had significant antitumor activity compared to chemotherapy alone in the first-line treatment of advanced gastric/gastroesophageal junction cancer. However, the combination therapy was associated with higher toxicity. The authors recommend PD-1 inhibitors plus chemotherapy as the optimal treatment regimen for patients with positive PD-1 ligand expression, in Asia, male and less than 65 years of age.
ANNALS OF MEDICINE AND SURGERY
(2023)
Article
Nanoscience & Nanotechnology
Ying Zhou, Mei Yang, Xiangji Yan, Lingmin Zhang, Ning Lu, Yana Ma, Yuanyuan Zhang, Manli Cui, Mingzhen Zhang, Mingxin Zhang
Summary: Ulcerativecolitis (UC), an inflammatory bowel disease, lacks effective therapies. This study developed a nanocarrier called AG/CORM-2@NP-Dex, which efficiently delivered the anti-inflammatory compound AG and CO donor CORM-2. The nanocarrier demonstrated anti-inflammatory and pro-resolving effects, making it a promising therapeutic approach for UC.
ACS APPLIED MATERIALS & INTERFACES
(2023)
Review
Biochemistry & Molecular Biology
Yunlong Liang, Mingzhen Zhang, Yujie Zhang, Mingxin Zhang
Summary: With the rapid development of sonodynamic therapy, sonosensitizers have transitioned from traditional treatments to comprehensive diagnostics and therapies. These sonosensitizers have been shown to play a crucial role in ultrasound imaging, X-ray computed tomography, and magnetic resonance imaging diagnostics, while also having therapeutic effects. This review discusses recent articles on multifunctional sonosensitizers used in sonodynamic therapy for cancer treatment, including their potential for clinical applications in ultrasound imaging, CT, and MRI. The review also highlights the shortcomings of current clinical examinations and the results of sonosensitizers in animal imaging. Furthermore, the paper provides insights into the future development and prospects of sonosensitizers for integrative diagnostics and therapeutics.
Editorial Material
Genetics & Heredity
Hao Liu, Ning Lu, Manli Cui, Mingxin Zhang
Summary: This study investigated the impact of vitamins and trace elements on the epigenetics of inflammatory bowel disease (IBD). Vitamins A, B, C, D, zinc and selenium were found to influence IBD through epigenetic changes. The findings provide valuable insights for nutrition, treatment and prevention strategies.
Meeting Abstract
Gastroenterology & Hepatology
Yuanyuan Su, Ning Lu, Qian Li, Hua Wen, Xiao Qing Zhang, Ming Xin Zhang
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Meeting Abstract
Gastroenterology & Hepatology
Yuanyuan Su, Ning Lu, Hua Wen, Jie Zhang, Jie Li, Ling Fan, Xin Quan, Ling Min Zhang, Ming Xin Zhang
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Engineering, Biomedical
Hao Liu, Yujie Zhang, Mingzhen Zhang, Zhaoxiang Yu, Mingxin Zhang
Summary: Platinum nanoparticles (Pt NPs) with enzyme-like activities can eliminate excessive reactive oxygen species (ROS) and alleviate ulcerative colitis (UC) symptoms in a colitis model. The oral administration of Pt NPs shows promising therapeutic potential for long-term inflammatory remission.
JOURNAL OF FUNCTIONAL BIOMATERIALS
(2023)
Article
Chemistry, Multidisciplinary
Zhichao Deng, Wenqi Ma, Chenguang Ding, Chaojun Wei, Bowen Gao, Yuanyuan Zhu, Yujie Zhang, Feng Wu, Mingxin Zhang, Runqing Li, Mingzhen Zhang
Summary: In this study, a nanomedicine delivery system based on metal polyphenol network/cerium oxide artificial enzymes (MPN@CeOx) was developed for the treatment of ulcerative colitis (UC) and the evaluation of inflammation severity using MRI/CT imaging. The results showed that the nanosystem effectively scavenged reactive oxygen species and reduced pro-inflammatory cytokines to protect cells from oxidative damage, and improved UC symptoms through inflammation-related signaling pathways.
Meeting Abstract
Gastroenterology & Hepatology
Yuanyuan Su, Ning Lu, Hua Wen, Jie Zhang, Jie Li, Ling Fan, Xin Quan, Ling Min Zhang, Ming Xin Zhang
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2023)
